Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders

被引：330
|
作者：
Zhang, Ao [1 ]
Neumeyer, John L.
Baldessarini, Ross J.
机构：
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Bioorgan & Med Chem Lab, Shanghai 201203, Peoples R China
[2] Harvard Univ, Sch Med, McLean Hosp, Med Chem Lab, Belmont, MA 02478 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA
[4] Harvard Univ, Sch Med, Program Neurosci, Belmont, MA 02178 USA
[5] McLean Hosp, Neuropharmacol Lab, Belmont, MA 02478 USA
来源：
CHEMICAL REVIEWS | 2007年 / 107卷 / 01期
关键词：
D O I：
10.1021/cr050263h
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
This review covers progress during 2000-2005 on the development of selective ligands targeting mainly to the five main dopamine (DA) receptors. Topics discussed include the pharmacology of dopamine receptor subtypes and the development of dopamine receptor subtype ligands. As for the latter, emphasis is on the receptor-selective ligands from D1 to D4. Generally, recent efforts in medicinal chemistry and neuropharmacology have yielded substantial numbers of compounds with activity and selectivity at each of these major DA receptors.
引用
收藏
页码：274 / 302
页数：29
相关论文
共 50 条
  • [41] Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A1 Receptor in Living Cells
    Comeo, Eleonora
    Trinh, Phuc
    Nguyen, Anh T.
    Nowell, Cameron J.
    Kindon, Nicholas D.
    Soave, Mark
    Stoddart, Leigh A.
    White, Jonathan M.
    Hill, Stephen J.
    Kellam, Barrie
    Halls, Michelle L.
    May, Lauren T.
    Scammells, Peter J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (10) : 6670 - 6695
  • [42] Recent Progress of Adenosine Receptor Modulators in the Development of Anticancer Chemotherapeutic Agents
    Marwein, Sarapynbiang
    Mishra, Bijayashree
    De, Utpal C.
    Acharya, Pratap C.
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (26) : 2842 - 2858
  • [43] Caffeine and selective adenosine antagonists reverse the effort-related motivational effects of impaired dopamine transmission: potential relevance for psychiatric and neurological disorders
    Salamone, J. D.
    Correa, M.
    Ferrigno, S.
    Yang, J. H.
    Rotolo, R. A.
    Presby, R. E.
    PURINERGIC SIGNALLING, 2018, 14 : S45 - S45
  • [44] Potential therapeutics for the treatment of psychiatric disorders: Design and synthesis of potent, selective, bioavailable 5HT2C receptor agonists
    Sabb, AL
    Vogel, RL
    Welmaker, GS
    Sabalski, J
    Nelson, J
    Stack, G
    Antane, M
    Mazandarani, H
    Zhang, J
    Dunlop, J
    Rosenzweig-Lipson, S
    Marquis, K
    Grauer, S
    Harrison, BL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U159 - U159
  • [45] Potent and Subtype-Selective Dopamine D2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach
    Mallo-Abreu, Ana
    Reyes-Resina, Irene
    Azuaje, Jhonny
    Franco, Rafael
    Garcia-Rey, Aitor
    Majellaro, Maria
    Miranda-Pastoriza, Dario
    Garcia-Mera, Xerardo
    Jespers, Willem
    Gutierrez-de-Teran, Hugo
    Navarro, Gemma
    Sotelo, Eddy
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (12) : 8710 - 8726
  • [46] A Two-Step Target Binding and Selectivity Support Vector Machines Approach for Virtual Screening of Dopamine Receptor Subtype-Selective Ligands
    Zhang, Jingxian
    Han, Bucong
    Wei, Xiaona
    Tan, Chunyan
    Chen, Yuzong
    Jiang, Yuyang
    PLOS ONE, 2012, 7 (06):
  • [47] The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies
    Toll, Lawrence
    Cippitelli, Andrea
    Ozawa, Akihiko
    CNS DRUGS, 2021, 35 (06) : 591 - 607
  • [48] The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies
    Lawrence Toll
    Andrea Cippitelli
    Akihiko Ozawa
    CNS Drugs, 2021, 35 : 591 - 607
  • [49] Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics
    Robichaud, Albert J.
    Engers, Darren W.
    Lindsley, Craig W.
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (08): : 433 - 449
  • [50] Recent progress in the development of selective S1P1 receptor agonists for the treatment of inflammatory and autoimmune disorders
    Buzard, Daniel J.
    Thatte, Jayant
    Lerner, Michael
    Edwards, Jeffrey
    Jones, Robert M.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (10) : 1141 - 1159
12345